|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.820 USD | +2.25% |
|
+13.04% | -2.67% |
| 07-11 | Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board | CI |
| 06-30 | Quince Therapeutics, Inc.(NasdaqGS:QNCX) added to Russell Microcap Growth Index | CI |
| Capitalization | 82.75M 70.76M 65.91M 61.31M 113M 7.1B 126M 790M 302M 3.32B 310M 304M 12.19B | P/E ratio 2025 * |
-1.88x | P/E ratio 2026 * | -2.68x |
|---|---|---|---|---|---|
| Enterprise value | 82.75M 70.76M 65.91M 61.31M 113M 7.1B 126M 790M 302M 3.32B 310M 304M 12.19B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
86.48% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Quince Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.25% | ||
| 1 week | +13.04% | ||
| Current month | +10.30% | ||
| 1 month | +51.67% | ||
| 3 months | +82.00% | ||
| 6 months | +1.68% | ||
| Current year | -2.67% |
| 1 week | 1.55 |  | 2.05 |
| 1 month | 1.29 | | 2.05 |
| Current year | 0.72 | | 2.05 |
| 1 year | 0.51 | | 2.45 |
| 3 years | 0.51 | | 2.72 |
| 5 years | 0.51 | | 121.98 |
| 10 years | 0.51 | | 121.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 55 | 19/05/2022 |
Charles Ryan
PSD | President | 60 | 01/09/2023 |
Brendan Hannah
DFI | Director of Finance/CFO | 40 | 16/03/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lamond
CHM | Chairman | 50 | 01/02/2022 |
| Director/Board Member | 61 | 01/12/2015 | |
Una Ryan
BRD | Director/Board Member | 83 | 01/01/2019 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0% | 293,477 M€ | -0.20% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.25% | +13.04% | +133.87% | -18.75% | 82.75M | ||
| -0.95% | +0.68% | +8.88% | +1.62% | 50.02B | ||
| -1.22% | +1.96% | +64.49% | +40.10% | 29.65B | ||
| 0.00% | +0.34% | +3.30% | +8.18% | 28.69B | ||
| -1.65% | -0.88% | -27.38% | -23.76% | 28.16B | ||
| -0.03% | -0.39% | +23.62% | -20.18% | 12.7B | ||
| -1.02% | +0.28% | -55.21% | -27.95% | 11.96B | ||
| -0.87% | +0.45% | +26.71% | +94.27% | 10.59B | ||
| -0.87% | -0.43% | +10.94% | -2.87% | 10.42B | ||
| -4.56% | -6.71% | +43.06% | - | 9.85B | ||
| Average | -0.89% | +1.39% | +23.23% | +5.63% | 19.21B | |
| Weighted average by Cap. | -1.07% | +0.63% | +11.20% | +6.65% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -47.06M -40.25M -37.49M -34.87M -64.42M -4.04B -71.59M -449M -172M -1.89B -177M -173M -6.94B | -50.85M -43.48M -40.5M -37.67M -69.61M -4.36B -77.36M -485M -186M -2.04B -191M -187M -7.49B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
36
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/07/25 | 1.820 $ | +2.25% | 494,899 |
| 10/07/25 | 1.780 $ | +4.09% | 370,847 |
| 09/07/25 | 1.710 $ | +6.21% | 274,307 |
| 08/07/25 | 1.610 $ | -1.23% | 212,494 |
| 07/07/25 | 1.630 $ | +1.24% | 253,336 |
Delayed Quote Nasdaq, July 12, 2025 at 04:00 am
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.820USD
Average target price
7.250USD
Spread / Average Target
+298.35%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- QNCX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition